GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (FRA:22Z) » Definitions » Shiller PE Ratio

Zealand Pharma AS (FRA:22Z) Shiller PE Ratio : (As of May. 01, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma AS Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zealand Pharma AS Shiller PE Ratio Historical Data

The historical data trend for Zealand Pharma AS's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS Shiller PE Ratio Chart

Zealand Pharma AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zealand Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zealand Pharma AS's Shiller PE Ratio

For the Biotechnology subindustry, Zealand Pharma AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Shiller PE Ratio falls into.


;
;

Zealand Pharma AS Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Zealand Pharma AS's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Zealand Pharma AS's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.552/118.9000*118.9000
=-0.552

Current CPI (Dec. 2024) = 118.9000.

Zealand Pharma AS Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.328 100.200 -0.389
201506 -0.456 100.300 -0.541
201509 -0.296 100.200 -0.351
201512 0.409 99.800 0.487
201603 -0.438 100.200 -0.520
201606 -0.551 100.600 -0.651
201609 -0.173 100.200 -0.205
201612 0.293 100.300 0.347
201703 -0.138 101.200 -0.162
201706 -0.496 101.200 -0.583
201709 -0.203 101.800 -0.237
201712 -0.488 101.300 -0.573
201803 -0.426 101.700 -0.498
201806 -0.482 102.300 -0.560
201809 4.016 102.400 4.663
201812 -0.570 102.100 -0.664
201903 -0.553 102.900 -0.639
201906 -0.580 102.900 -0.670
201909 -0.461 102.900 -0.533
201912 -0.726 102.900 -0.839
202003 -0.666 103.300 -0.767
202006 -0.211 103.200 -0.243
202009 -0.774 103.500 -0.889
202012 -1.301 103.400 -1.496
202103 -0.777 104.300 -0.886
202106 -0.924 105.000 -1.046
202109 -0.620 105.800 -0.697
202112 -0.873 106.600 -0.974
202203 -0.694 109.900 -0.751
202206 -1.483 113.600 -1.552
202209 -0.431 116.400 -0.440
202212 -0.906 115.900 -0.929
202303 -0.505 117.300 -0.512
202306 -0.739 116.400 -0.755
202309 0.165 117.400 0.167
202312 -0.617 116.700 -0.629
202403 -0.498 118.400 -0.500
202406 -0.626 118.500 -0.628
202409 -0.506 118.900 -0.506
202412 -0.552 118.900 -0.552

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zealand Pharma AS  (FRA:22Z) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Zealand Pharma AS Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma AS Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma AS Headlines

No Headlines